110221-44-8 Usage
Description
Temocapril is a novel ACE inhibitor marketed in Japan for the treatment of
hypertension. Temocapril is three times more potent than enalapril by oral
administration, and has a long duration of action. It is characterized by a rapid onset
of action resulting from a fast conversion of temocapril to the active metabolite
diacid. Unlike most ACE inhibitors which are excreted mainly through the kidneys,
temocapril is excreted predominantly through the biliary route indicating that
temocapril is especially useful for treating hypertensive patients with renal
dysfunction. The potential usefulness of temocapril in the treatment of congestive
heart failure has been reported.
Chemical Properties
White To Off-White Solid
Originator
Sankyo (Japan)
Uses
Different sources of media describe the Uses of 110221-44-8 differently. You can refer to the following data:
1. Angiotensin-converting enzyme (ACE) inhibitor. Hydrolyzed in vivo to the active diacid metabolite.
2. Angiotensin-converting enzyme (ACE) inhibitor. Hydrolyzed in vivo to the active diacid metabolite
3. angiotensin-converting enzyme inhibitor (ACE-I)
Brand name
Acecol
Check Digit Verification of cas no
The CAS Registry Mumber 110221-44-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,1,0,2,2 and 1 respectively; the second part has 2 digits, 4 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 110221-44:
(8*1)+(7*1)+(6*0)+(5*2)+(4*2)+(3*1)+(2*4)+(1*4)=48
48 % 10 = 8
So 110221-44-8 is a valid CAS Registry Number.
InChI:InChI=1/C23H28N2O5S2/c1-2-30-23(29)17(11-10-16-7-4-3-5-8-16)24-18-15-32-20(19-9-6-12-31-19)13-25(22(18)28)14-21(26)27/h3-9,12,17-18,20,24H,2,10-11,13-15H2,1H3,(H,26,27)/t17-,18-,20-/m0/s1
110221-44-8Relevant articles and documents
Angiotensin-Converting Enzyme Inhibitors: Perhydro-1,4-thiazepin-5-one Derivatives
Yanagisawa, Hiroaki,Ishihara, Sadao,Ando, Akiko,Kanazaki, Takuro,Miyamoto, Shuichi,et al.
, p. 1984 - 1991 (2007/10/02)
α-amino>-5-oxoperhydro-1,4-thiazepin-4-yl>acetic acids (monoester monoacids) and their dicarboxylic acids having the hydrophobic substituents at the 2- or 3-position of the thiazepinone ring were prepared and assayed for angiotensin-converting enzyme (ACE) inhibitory activity.The dicarboxylic acids having the pseudoequatorial amino groups at the 6-position and the pseudoequatorial hydrophobic substituents at the 2- or 3-position of the chair conformation of the thiazepinone ring had potent in vitro inhibitory activity.The monoester monoacids having the hydrophobic substituents at the 2-position suppressed pressor response to angiotensin I for a longer duration than those having the substituents at the 3-position when administered orally.The structure-activity relationship was studied by conformational energy calculations of the thiazepinone ring.
